Company Licenses Experimental Cancer Treatment to Treat Anaphylaxis


A biopharma company based in New York City has expanded it’s licensing agreement with North Carolina State University to include the development and commercialization of a therapeutic for a rare form of cancer as well as anaphylaxis.

Hoth Therapeutics — a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs — has licensed an investigational drug that targets tyrosine kinase KIT, a specific receptor on mast cells. Using the platform, Hoth hopes to target mast cell neoplasms, a rare and extremely aggressive form of cancer.

Click to visit sponsor

That same receptor target also plays a significant role in mast cell-mediated anaphylaxis, a serious, life-threatening reaction to an external antigen such as a food, insect venom, or latex. Hoth intends to pursue an anaphylaxis indication for the new drug in addition to the cancer treatment.

Said Robb Knie, CEO of Hoth Therapeutics:

We are delighted to expand this strategic alliance with NC State and our Scientific Advisory Board member, Dr. Glenn Cruse. We believe that the HT-KIT pathway is a promising novel target for combating both mast cell-derived cancers and mast cell-mediated anaphylaxis. This expanded license agreement highlights the broad potential of our diverse pipeline that is aimed at meeting critical unmet patient needs and further supports Hoth’s strategy to build a sustainable therapeutics company that is patient focused.

Print or share this article
Click to visit sponsor
Dave Bloom
Dave Bloom
Dave Bloom is CEO and "Blogger in Chief" of

Find Allergy-Friendly Products